A global intelligence publication covering biotechnology, artificial intelligence, drug discovery, synthetic biology, and life-science innovation.
The Great Therapeutic Divide
The Strathmore 2026 Report
Join leaders, innovators and professionals across artificial intelligence and biotechnology for an evening focused on industry insights, new connections and meaningful collaboration.
A new comprehensive review published in the Journal of Nanoparticle Research surveys one of the most quietly promising corners of…
Read Article →
The Food and Drug Administration is announcing a public hearing on the potential future therapeutic use of psychedelic drugs.
Read Article →
BIOCENTURY | MANAGEMENT TRACKSTAKEDA’S PLUMP, GV’S YESHWANT ANNOUNCE RETIREMENT PLANSAndy Plump has helped remake Japanese pharma an innovative global player
Read Article →
A late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve…
Read Article →
By reproducing elements of human bone marrow on a chip, scientists have created a new tool that will help them…
Read Article →
RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific…
Read Article →
Following formal sign-off from the FDA, Handa Pharmaceuticals’ branded drug reformulation strategy has paid off for a third time.
Read Article →
At NLS Days 2026, life science companies and a record number of investors attended to showcase data, partner, and raise…
Read Article →A new comprehensive review published in the Journal of Nanoparticle Research surveys one of the most quietly promising corners of nanomedicine: carbon dots, nanoscale specks of carbon that are showing…
Read Article →The Food and Drug Administration is announcing a public hearing on the potential future therapeutic use of psychedelic drugs.
Read Article →By reproducing elements of human bone marrow on a chip, scientists have created a new tool that will help them…
Read Article →
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Read Article →
The polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation therapies, playing catch-up to…
Read Article →A landmark multi-institution study has revealed that the neighborhood a patient with metastatic breast cancer lives in may be written into the biology of the tumor itself. Researchers analyzing more…
Read Article →
Researchers used DNA sequencing to map mutations in normal tissue from cancer patients undergoing different types of treatment. They found…
Read Article →
AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with…
Read Article →
GSK’s risvutatug rezetecan has achieved a median overall survival of 18.5 months in a phase 3 trial, painting the antibody-drug…
Read Article →
An ongoing shortage of cancer medications continues to force leading cancer centers around the U.S. to seek work-around strategies to…
Read Article →
A late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year.
Read Article →
Following formal sign-off from the FDA, Handa Pharmaceuticals’ branded drug reformulation strategy has paid off for a third time.
Read Article →
Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for…
Read Article →Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed…
Read Article →
Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.
Read Article →
The agreement involves the use of Modalis’ CRISPR-GNDM (Guide Nucleotide-Directed Modulation) technology in combination with Exegenesis Bio’s engineered muscle-tropic adeno-associated…
Read Article →
Shinshu University Hospital's expertise in CAR T-cell therapy R&D and clinical application will be combined with Teijin Regenet's manufacturing and…
Read Article →
Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
Read Article →
Encoded Therapeutics’ lead asset ETX101 is a gene therapy being tested for Dravet syndrome. Phase 1/2 data showed substantial reductions…
Read Article →Bacterial wilt, caused by the soil-borne pathogen Ralstonia solanacearum, is one of the most destructive plant diseases in the world, striking tomatoes, potatoes, bananas and hundreds of other crops. Once…
Read Article →
Alongside decisions involving capacity expansion, officials at Samsung Biologics announced that the company is pursuing opportunities to broaden its portfolio…
Read Article →
A ribbon-cutting ceremony to mark the opening is scheduled for 24 September, with company leadership, employees, partners and community leaders…
Read Article →
Argonaut Manufacturing Services, a CDMO specializing in aseptic fill-finish for injectable biologics and other drugs, has sold its life sciences…
Read Article →
Merck pursues new cancer combinations, prediction markets put pharma’s confidential information in focus and personalized cancer vaccines confront manufacturing hurdles.
Read Article →
The Eco-NAMs Webinar Series aims to present the most informative and up-to-date science on new approach methodologies (NAMs) for ecotoxicity assessments
Read Article →RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific…
Read Article →
Novartis investors are stepping up scrutiny of the company's dealmaking after setbacks to drugs it acquired through mergers and acquisitions
Read Article →At NLS Days 2026, life science companies and a record number of investors attended to showcase data, partner, and raise…
Read Article →
Our round-up of biotech financings is headed by Encoded, which has raised $275m to advance its gene therapy for Dravet…
Read Article →
BIOCENTURY | MANAGEMENT TRACKSTAKEDA’S PLUMP, GV’S YESHWANT ANNOUNCE RETIREMENT PLANSAndy Plump has helped remake Japanese pharma an innovative global player
Read Article →
An E.U. AG recommended annulling part of a directive that requires drugmakers to finance 80% of the costs of wastewater…
Read Article →
The agreement, which runs through 2033, comes as Samsung Biologics continues to expand its large manufacturing footprint in South Korea.
Read Article →
A report has concluded that the current regulatory framework in the UK is inadequate for healthcare AI, and makes 44…
Read Article →
Takeda's long-time R&D chief Andy Plump will retire. Daiichi Sankyo beat back a $1.3 billion damage claim in a lawsuit.…
Read Article →
Johns Hopkins researchers developed CloudScope, a cloud-based microscope enabling continuous, remote brain imaging in freely moving mice, revealing disease progression, seizures, cellular changes and behavior over extended periods. The post…
Read Article →
Newly solidified in their roles as the heads of CBER and CDER, Karim Mikahil and Michael Davis have been working…
Read Article →
Melanoma remains one of the most aggressive and treatment-resistant forms of human cancer, and although immune checkpoint inhibitors have transformed…
Read Article →
An AI-based imaging tool from Brainomix has been used to enrich data from a phase 2a trial of Endeavor's idiopathic…
Read Article →
The Liverpool Accelerate Laboratory was developed with the LSTM-led iiCON: Infection Innovation Consortium and received funding from the Liverpool City…
Read Article →Receive curated biotechnology intelligence, executive interviews, and publication updates delivered to your inbox.
Scan to Read
